5 Insightful Analyst Inquiries from Bausch + Lomb’s Fourth Quarter Earnings Call

Bausch + Lomb Q4 Results: Revenue Growth and Strategic Shifts

Bausch + Lomb reported solid revenue gains in the fourth quarter, though adjusted earnings per share did not meet analyst forecasts, resulting in a slight downturn in market sentiment. Company leadership credited the strong performance to continued success in their dry eye treatment portfolio—especially Miebo—and enhanced operational efficiency driven by disciplined cost management. CEO Brenton Saunders highlighted the positive effects of the Vision 27 initiative, noting a deliberate move toward higher-margin offerings and improved pricing strategies. Saunders stated that the quarter’s results demonstrate the benefits of Vision 27, which focuses on optimizing product mix, boosting productivity, and maintaining a more stable cost structure.

Should You Consider Investing in BLCO?

Key Takeaways from Bausch + Lomb’s Q4 2025

• Revenue: $1.41 billion, surpassing analyst projections of $1.38 billion (9.8% year-over-year increase, 1.5% above expectations)
• Adjusted EPS: $0.32, below the anticipated $0.36 (10.3% shortfall)
• Adjusted EBITDA: $330 million, exceeding the $320.7 million estimate (23.5% margin, 2.9% beat)
• Operating Margin: 8%, up from 6.8% in the prior year’s comparable period
• Constant Currency Revenue: 7% annual growth (compared to 11% in the same quarter last year)
• Market Cap: $6.53 billion

While management’s prepared remarks are informative, analyst Q&A sessions often reveal deeper insights and address challenging topics. Here are some of the most notable analyst questions from the call:

Top 5 Analyst Questions from the Q4 Earnings Call

• Patrick Wood (Morgan Stanley): Asked about the drivers of growth in 2026 and the influence of Q4 momentum by product category. CEO Saunders pointed to disciplined execution and structural enhancements as primary growth catalysts.
• Young Li (Jefferies): Queried the competitive environment for contact lenses, surgical devices, and dry eye therapies. Saunders and Stewart described their market position as robust, citing ongoing product launches and steady growth in China, while acknowledging intensifying competition.
• Joanne Wuensch (Citibank): Requested updates on clinical results for the new bioactive contact lens material. Saunders and R&D head Yehia Hashad shared encouraging early data and expressed confidence in the platform, with a launch targeted for 2028.
• Lei Huang (Wells Fargo): Sought expectations for Xiidra’s growth and margin improvements. Stewart discussed a focus on optimizing net pricing despite slower prescription growth, and Eldessouky outlined strategies for enhancing gross and SG&A margins.
• Lilia-Celine Lozada (JPMorgan): Asked about the path to achieving a 19% EBITDA margin and details on SG&A leverage. Eldessouky explained that gains would come from better gross margins, SG&A efficiencies, and prudent R&D spending, all supported by ongoing cost controls.

Upcoming Catalysts to Watch

Looking ahead, analysts will be closely tracking:

• Continued growth and profitability in the dry eye segment, especially as Miebo and Xiidra mature
• Market adoption and clinical feedback for new launches like PreserVision AREDS3 and advanced contact lenses
• The company’s ability to sustain operating leverage and margin improvements amid competitive and tariff challenges
• Progress on R&D milestones and successful international expansion

Bausch + Lomb shares recently traded at $18.42, up from $17.73 prior to the earnings release. Interested in the investment opportunity?

Resilient Stocks for Every Market Environment

Relying on just a handful of stocks can leave your portfolio vulnerable. Now is the time to secure high-quality investments before the market broadens and current valuations disappear.

Don’t wait for the next market shock. Explore our Top 6 Stocks for This Week—a handpicked selection of high-quality companies that have delivered a 244% return over the past five years (as of June 30, 2025).

Our list features well-known names like Nvidia, which soared 1,326% from June 2020 to June 2025, as well as lesser-known success stories such as Comfort Systems, which achieved a 782% five-year return. Discover your next top performer with StockStory today.